10.22.2025
Tokyo, Japan – Fast Track Initiative, Inc. (FTI) today announced the successful closing of Fast Track Initiative Fund IV (Fund IV) with total committed capital of 20 billion JPY (approximately 130 million USD).
FTI is one of the largest healthcare-focused venture funds in Japan with Fund IV marking a significant milestone in FTI’s mission to realize “Capital For Life” – leveraging FTI’s expanding network across Japan and globally to advance innovative medicines and transformative healthcare solutions.
Over 90% of Fund IV’s commitments come from institutional investors, including leading domestic pension funds and financial institutions, alongside strong recommitments from existing Fund III investors. The closing marks a significant milestone for FTI, building on over 20 years of experience investing in healthcare innovation.
“We are deeply grateful for the confidence our investors have placed in our mission to advance healthcare innovation from Japan to the world,” said Tomo Anzai, PhD, Managing Partner of FTI. “Fund IV will enable us to continue supporting visionary scientists and entrepreneurs who are building the next generation of life-changing therapeutics and medical technologies.”
From Life Science to Healthcare Value
FTI Fund IV invests across the healthcare innovation spectrum—from early-stage science through clinical validation—supporting companies developing novel medicines for diseases with highest unmet needs.
FTI’s portfolio companies have demonstrated significant healthcare contributions over the past 21 years continuously translating academic breakthroughs into clinical value and healthcare impact. These include 70 programs in pre-clinical development, 19 in clinical development, 24 active clinical trials with 445 patients, and 1 approved product.
Fund IV portfolio includes Regcell, a company developing breakthrough therapies for autoimmune diseases based on regulatory T cell technology pioneered by 2025 Nobel laureate, Dr. Shimon Sakaguchi.
Riding Japan’s Venture Wave
Japan has become as an increasingly attractive ground for life science innovation. It has established itself as a wellspring of groundbreaking scientific innovation, consistently discovering novel sciences that are later translated into transformative medicines that advance global healthcare. Today, this momentum is accelerating by supportive business environment.
Government funding agencies, including AMED (Japan Agency for Medical Research and Development), are providing robust support for biotech pipeline development through human POC, positioning Japan as a globally competitive innovation hub. Simultaneously, institutional investors are actively allocating capital to healthcare-focused venture funds, signaling growing confidence in investing in biotech and healthcare.
“We’re at an exciting inflection point where Japanese biotech and venture are beginning to receive more recognition” said Tai Harada, Partner at FTI. “Fund IV positions us to help bridge Japan’s innovations with global healthcare markets, while also giving global partners access to Japan’s increasingly robust venture landscape.”
Integrating Japanese Science and Global Capabilities to Accelerate Innovation
FTI is one of Japan’s pioneering healthcare venture firms, bringing 21 years of experience identifying, investing and scaling breakthrough science and companies alongside leading researchers and entrepreneurs. In 2019, FTI expanded its footprint by opening a US office to further enable global execution.
Fund IV will leverage this Japan-US integration to accelerate the global execution of healthcare innovations, combining FTI’s scientific credibility with operational expertise and global capital access.
FTI’s team combines high degree of scientific depth with business acumen—a model that has proven effective in translating academic breakthroughs into successful companies. Fund IV reinforces this capability by welcoming global advisors who bring expertise in venture investment and startup management.
Advisors include:
- Keith Crandell, Co-Founder and Managing Director, ARCH Venture Partners
- Evan Rachlin, MD, Co-Founder and Managing Partner, Ascenta Capital
- Tariq Kassum, MD, CXO, Curie Bio; Former CEO, Celsius Therapeutics (FTI portfolio company, acquired by AbbVie)
- Tetsuyuki Maruyama, PhD, Venture Partner, Dementia Discovery Fund at SV Health Investors; Former Head of Drug Discovery, Takeda Pharmaceuticals
FTI also welcomed Natalie Roy D’Amore, PhD, as Venture Partner in its Boston office. D’Amore brings deep expertise in partnerships and strategy, including Head of Oncology Partnerships and Strategy at Takeda Pharmaceuticals.
Working alongside portfolio company partners and colleagues around the world, FTI is committed to accelerating the creation and development of life science solutions that will benefit patients globally.
Read the full coverage in Endpoints News: https://endpoints.news/japans-fast-track-initiative-announces-new-130m-venture-fund/
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services. The company provides valuable, hands-on expertise to its 40+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.
Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/
